RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Camptothecin .beta.-alanine esters with topoisomerase I inhibition

Wall, M., Wani, M., Manikumar, G., Balasubramanian, N., & Vyas, D. (2001). Camptothecin .beta.-alanine esters with topoisomerase I inhibition. (U.S. Patent No. 6288072). http://patft.uspto.gov/netacgi/nph-Parser?patentnumber=6288072

Abstract

.beta.-Alanine esters of camptothecin compounds which are effective anti-tumor compounds are disclosed. These compounds inhibit the enzyme topoisomerase I and may alkylate DNA of the associated topoisomerase I-DNA cleavable complex.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Developing capacity in identifying cost-effective interventions to prevent and reduce obesity in China
Article

US consumer and healthcare professional preferences for combination COVID-19 and influenza vaccines
Article

Comparing youth-friendly clinics to the standard of care for adolescent girls and young women in Malawi: A qualitative analysis
Article

Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial